REGENXBIO Inc.

RGNX Nasdaq CIK: 0001590877

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Accelerated filer
Business Address 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
Mailing Address 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
Phone 240-552-8181
Fiscal Year End 1231
EIN 471851754

Financial Overview

FY2024

-$227.10M
Net Income
$573.97M
Total Assets
$262.23M
Total Liabilities
$96.95M
Cash & Equivalents

Recent SEC Filings

Form Type Date Filed Document
424B5 Prospectus supplement February 12, 2026 View on SEC
8-K Current report of material events February 10, 2026 View on SEC
4 Insider stock transaction report February 3, 2026 View on SEC
4 Insider stock transaction report February 3, 2026 View on SEC
4 Insider stock transaction report January 29, 2026 View on SEC
8-K Current report of material events January 28, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment January 21, 2026 View on SEC
4 Insider stock transaction report January 8, 2026 View on SEC
4 Insider stock transaction report January 8, 2026 View on SEC
4 Insider stock transaction report January 8, 2026 View on SEC

Material Events

8-K Other February 10, 2026
High Impact
  • REGENXBIO is committed to finding a path forward for RGX-121 despite the setback.
  • The company has approximately $400 million in cash and equivalents, providing some financial runway.
View Analysis
8-K Other January 28, 2026
High Impact
  • Targeting severe, rare genetic disorders (MPS I and MPS II) with desperately needed treatments.
  • RGX-111 and RGX-121 are crucial assets in its pipeline.
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.